Open discussion about peptide research
More Research Use Only peptide companies are starting to announce that they are “moving into telehealth,” “partnering with doctors,” or plan
Over the past several months, one of the biggest changes I’ve noticed while watching VialTalk grow is how much the peptide market itself is
The market is moving in two very different directions right now. On one side, we are seeing more vendors move toward heavier testing, full-p
The peptide space looks different than it did even a year ago. Some observations. GLP-1 went mainstream. Semaglutide and tirzepatide changed
